BillionToOne is a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all.
BillionToOne is the only genetic testing platform that accurately and efficiently detects and measures disease at the molecular level.
BillionToOne was founded in 2016 by Oguzhan Atay and David Tsao. The company is headquartered in Palo Alto, California.
BillionToOne's Quantitative Counting Templates, QCTs, enable counting DNA molecules at the single-count level with single base-pair precision. BillionToOne’s cancer diagnostic test lowers the limit of detection for gene amplifications by 10x so that these hallmarks of cancer are detected earlier.
BillionToOne’s first product, UNITY Screen™ is the only commercially available non-invasive prenatal test (NIPT) that assesses fetal risk for recessive conditions and red blood cell antigen incompatibility.
BillionToOne is also launching its liquid biopsy product line, Northstar Select™ and Northstar Response™, in early 2023. BillionToOne's molecular counting technology increases the resolution of disease detection using cell-free DNA by over 1000-fold.
BillionToOne is backed by Adams Street Partners, Hummingbird Ventures, Baillie Gifford, Neotribe Ventures, Norwest Venture Partners, Bridge Bank, Y Combinator, Libertus Capital, Pacific 8 Ventures, Civilization Ventures, and others. The company secured an additional $48.5M in equity and $35M in Loan Facility on Dec 15, 2022. This brings BillionToOne's total funding to $295.9M to date.